• Users Online: 85
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 34  |  Issue : 2  |  Page : 108-112

Aspirin versus low-molecular-weight heparin in treating recurrent miscarriages in women without antiphospholipid antibody syndrome

1 Department of Obstetrics and Gynecology, Faculty of Medicine, Al-Azher University, Cairo, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Al-Azher University, Cairo, Egypt
3 Department of Obstetrics and Gynecology, El-Galaa Maternity Teaching Hospital, Cairo, Egypt

Correspondence Address:
Osama M Hamoda
345 Faisl Street, Giza, Cairo, 12555
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/bmfj.bmfj_20_17

Rights and Permissions

Background As hypercoagulability may result in recurrent miscarriages, anticoagulants (clexane) and aspirin (aspocid) could potentially increase live-birth rate in subsequent pregnancies in women with either inherited thrombophilia or unexplained recurrent miscarriages. Patients and methods This randomized trial included 120 pregnant women who were recruited by the closed-envelope method from the outpatient clinics of El-Hussien University Hospital and El-Galaa Maternity Teaching Hospital with history of at least three recurrent miscarriages. The trial was designed to compare the effects of low-dose aspirin (aspocid 75 mg tab) and low-molecular-weight heparin (LMWH) (clexane) on pregnancy outcome and live-birth rate. Pregnant women were divided into two groups: group 1 (60) was administered oral, low-dose aspirin (aspocid 75 mg tab) daily, and group 2 (60) was administered LMWH (clexane) 1 mg/kg subcutaneously daily. Results Regarding primary outcome (live-birth rate), the two groups did not differ significantly. Both drugs increased live-birth rate with an incidence of 81.7% in group 1 and 83.3% in group 2. Conclusion Low-dose aspirin (aspocid 75 mg tab) and LMWH (clexane 1 mg/kg) improve pregnancy outcome and increase live-birth rate, with no significant differences between the two drugs in patients with history of recurrent miscarriages without antiphospholipid antibody syndrome.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded242    
    Comments [Add]    

Recommend this journal